Department of Defense Protocol for the Use of Sodium Stibogluconate (Pentostam) as a Treatment for Leishmaniasis

Trial Profile

Department of Defense Protocol for the Use of Sodium Stibogluconate (Pentostam) as a Treatment for Leishmaniasis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 May 2017

At a glance

  • Drugs Sodium stibogluconate (Primary)
  • Indications Cutaneous leishmaniasis; Visceral leishmaniasis
  • Focus Adverse reactions
  • Most Recent Events

    • 07 May 2017 Status changed from recruiting to completed.
    • 24 Oct 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2016.
    • 20 Apr 2015 Trial focus and trial phase has been changed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top